Case Report| Volume 15, ISSUE 6, e1127-e1130, December 2017

Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma

      Chromophobe renal cell carcinoma (CRCC) is the third most common subtype of renal cell carcinoma (RCC).


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Leibovich B.C.
        • Lohse C.M.
        • Crispen P.L.
        • et al.
        Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
        J Urol. 2010; 183: 1309-1315
        • Amin M.B.
        • Paner G.P.
        • Alvarad-Cabrero I.
        • et al.
        Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.
        Am J Surg Pathol. 2008; 32: 1822-1834
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Klatte T.
        • Han K.R.
        • Said J.W.
        • et al.
        Pathobiology and prognosis of chromophobe renal cell carcinoma.
        Urol Oncol. 2008; 26: 604-609
        • Geynisman D.M.
        Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features.
        Eur Urol. 2015; 68: 2015-2017
        • Ruiz-Banobre J.
        • Anido U.
        • Abdulkader I.
        • et al.
        Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report.
        Front Oncol. 2016; 6: 250
        • Rimar K.J.
        • Meeks J.J.
        • Kuzel T.M.
        Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma.
        Clin Genitourin Cancer. 2016; 14: e431-e434
        • Adra N.
        • Cheng L.
        • Pili R.
        Unclassified renal cell carcinoma with significant response to nivolumab.
        Clin Genitourin Cancer. 2017; 15: e517-e519
        • Adrianzen Herrera D.A.
        • Fleisig S.B.
        • Gartrell B.A.
        Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: in-label but without evidence.
        Invest New Drugs. 2017; (Epub ahead of print)
        • Choueiri T.K.
        • Fay A.P.
        • Gray K.P.
        • et al.
        PD-L1 expression in non-clear cell renal cell carcinoma.
        Ann Oncol. 2014; 25: 2178-2184